Here are four things to know:
1. SI-BONE booked $52 million in revenue for the 12 months ending June 30.
2. Morgan Stanley and Bank of America Merrill Lynch are the deal’s joint bookrunners.
3. Pricing terms were not disclosed.
4. SI-BONE develops the iFuse Implant System, a minimally invasive sacroiliac joint disorder treatment.
More articles on devices:
NuVasive welcomes CEO of Google, Johnson & Johnson partnership company to board
Medtronic adds to spine business with $1.64B acquisition of Mazor: 6 things to know
SpineEx files for $17M IPO: 3 notes
